RCT | Aflibercept monotherapy or bevacizumab first for diabetic macular edema.
18 Jul, 2022 | 11:16h | UTCAflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Some insurance companies mandate a form of step therapy, which involves a trial of an inexpensive drug, bevacizumab, to treat diabetic macular edema. This trial compared two treatments: step therapy and a more expensive drug. #ASRS2022 https://t.co/gOhFTw1C1T pic.twitter.com/8uN9WgmtkD
— NEJM (@NEJM) July 14, 2022